362 related articles for article (PubMed ID: 17846102)
1. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.
Pollock BG; Mulsant BH; Rosen J; Mazumdar S; Blakesley RE; Houck PR; Huber KA
Am J Geriatr Psychiatry; 2007 Nov; 15(11):942-52. PubMed ID: 17846102
[TBL] [Abstract][Full Text] [Related]
2. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients.
Pollock BG; Mulsant BH; Rosen J; Sweet RA; Mazumdar S; Bharucha A; Marin R; Jacob NJ; Huber KA; Kastango KB; Chew ML
Am J Psychiatry; 2002 Mar; 159(3):460-5. PubMed ID: 11870012
[TBL] [Abstract][Full Text] [Related]
3. Antidepressants for agitation and psychosis in dementia.
Seitz DP; Adunuri N; Gill SS; Gruneir A; Herrmann N; Rochon P
Cochrane Database Syst Rev; 2011 Feb; (2):CD008191. PubMed ID: 21328305
[TBL] [Abstract][Full Text] [Related]
4. Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms.
Dombrovski AY; Mulsant BH; Ferrell RE; Lotrich FE; Rosen JI; Wallace M; Houck PR; Mazumdar S; Pollock BG
Int Clin Psychopharmacol; 2010 Jan; 25(1):37-45. PubMed ID: 19996755
[TBL] [Abstract][Full Text] [Related]
5. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
6. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
[TBL] [Abstract][Full Text] [Related]
7. Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial.
Culo S; Mulsant BH; Rosen J; Mazumdar S; Blakesley RE; Houck PR; Pollock BG
Alzheimer Dis Assoc Disord; 2010; 24(4):360-4. PubMed ID: 20625270
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the E-BEHAVE-AD, NBRS, and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia.
Ismail Z; Emeremni CA; Houck PR; Mazumdar S; Rosen J; Rajji TK; Pollock BG; Mulsant BH
Am J Geriatr Psychiatry; 2013 Jan; 21(1):78-87. PubMed ID: 23290205
[TBL] [Abstract][Full Text] [Related]
9. Risperidone for the treatment of behavioral and psychological symptoms of dementia.
Tune LE
J Clin Psychiatry; 2001; 62 Suppl 21():29-32. PubMed ID: 11584986
[TBL] [Abstract][Full Text] [Related]
10. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study.
Barak Y; Plopski I; Tadger S; Paleacu D
Int Psychogeriatr; 2011 Nov; 23(9):1515-9. PubMed ID: 21492498
[TBL] [Abstract][Full Text] [Related]
11. Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics.
Aupperle P
Am J Alzheimers Dis Other Demen; 2006; 21(2):101-8. PubMed ID: 16634465
[TBL] [Abstract][Full Text] [Related]
12. Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation).
Ostinelli EG; Hussein M; Ahmed U; Rehman FU; Miramontes K; Adams CE
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD009412. PubMed ID: 29634083
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
14. Treatment strategies for agitation and psychosis in dementia.
Tariot PN
J Clin Psychiatry; 1996; 57 Suppl 14():21-9. PubMed ID: 9024333
[TBL] [Abstract][Full Text] [Related]
15. Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice.
Kurz A; Schwalen S S; Schmitt A
Int Psychogeriatr; 2005 Dec; 17(4):605-16. PubMed ID: 16185378
[TBL] [Abstract][Full Text] [Related]
16. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.
Villari V; Rocca P; Fonzo V; Montemagni C; Pandullo P; Bogetto F
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):405-13. PubMed ID: 17900775
[TBL] [Abstract][Full Text] [Related]
17. Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone.
Rabinowitz J; Katz IR; De Deyn PP; Brodaty H; Greenspan A; Davidson M
J Clin Psychiatry; 2004 Oct; 65(10):1329-34. PubMed ID: 15491235
[TBL] [Abstract][Full Text] [Related]
18. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease.
Workman RH; Orengo CA; Bakey AA; Molinari VA; Kunik ME
J Neuropsychiatry Clin Neurosci; 1997; 9(4):594-7. PubMed ID: 9447503
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis.
Kongpakwattana K; Sawangjit R; Tawankanjanachot I; Bell JS; Hilmer SN; Chaiyakunapruk N
Br J Clin Pharmacol; 2018 Jul; 84(7):1445-1456. PubMed ID: 29637593
[TBL] [Abstract][Full Text] [Related]
20. Update on SSRI Treatment for Neuropsychiatric Symptoms of Dementia.
Wilkins JM; Forester BP
Curr Psychiatry Rep; 2016 Feb; 18(2):14. PubMed ID: 26781552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
